## Abstract Specific cell‐mediated immunity to SV40 tumor‐specific transplantation antigen (TSTA) in BALB/c mice undergoing progressive tumorigenesis by syngeneic SV40‐transformed cells (VLM) was investigated in vivo using a tumor‐cell neutralization test. Specific cellular reactivity to SV40 TSTA
Peptide immunization excludes antigen-specific T cells from splenic lymphoid compartments
✍ Scribed by Lei Zhang; Elaine F. Lizzio; Trina Chen; Steven Kozlowski
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 622 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0014-2980
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Using adoptive transfer of TCR‐transgenic T cells, we examined the homing of transgenic T cells to splenic compartments in situ. After systemic immunization with peptide or protein antigen, the location of clonotypic T cells, cytokine production, cell surface markers, and apoptosis were assessed. There were distinct differences in the splenic homing of CD4^+^ TCR‐transgenic T cells in mice immunized with peptide as compared to mice immunized with whole‐protein antigen. T cells in peptide‐immunized mice were found almost exclusively in the splenic red pulp, but not in the T and B cell zones (white pulp), while the majority of T cells immunized with whole protein were found in the white pulp. Many more Fas ligand‐expressing and apoptotic cells were present after peptide immunization than after whole‐protein immunization. Localization of IL‐4‐, IL‐2‐ and IFN‐γ‐producing cells to the lymphocyte‐containing splenic white pulp was only observed with whole‐protein immunization. The unique homing and increased apoptosis of immune cells post peptide immunization may help explain the ineffectiveness of many peptide vaccines. Linkage of the same peptide epitope to a carrier protein increased white pulp T cell localization and decreased apoptosis, suggesting a strategy to enhance peptide vaccine responses.
📜 SIMILAR VOLUMES
## BACKGROUND. In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS. Phase II subjects received six administrations of aut
## Abstract Evidence is presented for specific in vitro killing of neoplastic target cells in the presence of non‐sensitized lymphoid cells and heat decomplemented sera from mice bearing the respective neoplasms or whose tumors had been removed. Such an effect was observed with sera from mice beari
## BACKGROUND. Conventional treatment for metastatic prostate cancer have failed to demonstrate curative potential in all patients. Investigations involving the role of T-cell immunity in the clearance of neoplastic cells are now available. Development of T-cell immunotherapy may give a new approa